Literature DB >> 21121053

Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.

Benjamin J Grady1, Eric S Torstenson, Paul J McLaren, Paul I W DE Bakker, David W Haas, Gregory K Robbins, Roy M Gulick, Richard Haubrich, Heather Ribaudo, Marylyn D Ritchie.   

Abstract

Personalized medicine is a high priority for the future of health care. The idea of tailoring an individual's wellness plan to their unique genetic code is one which we hope to realize through the use of pharmacogenomics. There have been examples of tremendous success in pharmacogenomic associations however there are many such examples in which only a small proportion of trait variance has been explained by the genetic variation. Although the increased use of GWAS could help explain more of this variation, it is likely that a significant proportion of the genetic architecture of these pharmacogenomic traits are due to complex genetic effects such as epistasis, also known as gene-gene interactions, as well as gene-drug interactions. In this study, we utilize the Biofilter software package to look for candidate epistasis contributing to risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens in treatment-naïve participants of AIDS Clinical Trials Group (ACTG) randomized clinical trials. A total of 904 individuals from three ACTG trials with data on efavirenz treatment are analyzed after race-stratification into white, black, and Hispanic ethnic groups. Biofilter was run considering 245 candidate ADME (absorption, distribution, metabolism, and excretion) genes and using database knowledge of gene and protein interaction networks to produce approximately 2 million SNP-SNP interaction models within each ethnic group. These models were evaluated within the PLATO software package using pair wise logistic regression models. Although no interaction model remained significant after correction for multiple comparisons, an interaction between SNPs in the TAP1 and ABCC9 genes was one of the top models before correction. The TAP1 protein is responsible for intracellular transport of antigen to MHC class I molecules, while ABCC9 codes for a transporter which is part of the subfamily of ABC transporters associated with multi-drug resistance. This study demonstrates the utility of the Biofilter method to prioritize the search for gene-gene interactions in large-scale genomic datasets, although replication in a larger cohort is required to confirm the validity of this particular TAP1-ABCC9 finding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21121053      PMCID: PMC3094912          DOI: 10.1142/9789814335058_0027

Source DB:  PubMed          Journal:  Pac Symp Biocomput        ISSN: 2335-6928


  27 in total

Review 1.  Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans.

Authors:  Heather J Cordell
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

Review 2.  Detecting epistatic interactions contributing to quantitative traits.

Authors:  Robert Culverhouse; Tsvika Klein; William Shannon
Journal:  Genet Epidemiol       Date:  2004-09       Impact factor: 2.135

3.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Authors:  S Hetherington; S McGuirk; G Powell; A Cutrell; O Naderer; B Spreen; S Lafon; G Pearce; H Steel
Journal:  Clin Ther       Date:  2001-10       Impact factor: 3.393

Review 4.  Antiretroviral therapy in the clinic.

Authors:  Athe M N Tsibris; Martin S Hirsch
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

5.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

6.  Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Robert W Shafer; Laura M Smeaton; Gregory K Robbins; Victor De Gruttola; Sally W Snyder; Richard T D'Aquila; Victoria A Johnson; Gene D Morse; Mostafa A Nokta; Ana I Martinez; Barbara M Gripshover; Pamposh Kaul; Richard Haubrich; Mary Swingle; S Debra McCarty; Stefano Vella; Martin S Hirsch; Thomas C Merigan
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

7.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.

Authors:  Alejandro Dorenbaum; Coleen K Cunningham; Richard D Gelber; Mary Culnane; Lynne Mofenson; Paula Britto; Claire Rekacewicz; Marie-Louise Newell; Jean Francois Delfraissy; Bethann Cunningham-Schrader; Mark Mirochnick; John L Sullivan
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Authors:  Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

10.  A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.

Authors:  David W Haas; Grant R Wilkinson; Daniel R Kuritzkes; Douglas D Richman; Janet Nicotera; Laura F Mahon; Cara Sutcliffe; Sue Siminski; Janet Andersen; Kristine Coughlin; Ellen W Clayton; Jonathan Haines; Ann Marshak; Michael Saag; Jody Lawrence; Jeffrey Gustavson; Jo Anne Bennett; Rolf Christensen; Margaret A Matula; Alastair J J Wood
Journal:  HIV Clin Trials       Date:  2003 Sep-Oct
View more
  10 in total

1.  Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts.

Authors:  Rishika De; Shefali S Verma; Emily Holzinger; Molly Hall; Amber Burt; David S Carrell; David R Crosslin; Gail P Jarvik; Helena Kuivaniemi; Iftikhar J Kullo; Leslie A Lange; Matthew B Lanktree; Eric B Larson; Kari E North; Alex P Reiner; Vinicius Tragante; Gerard Tromp; James G Wilson; Folkert W Asselbergs; Fotios Drenos; Jason H Moore; Marylyn D Ritchie; Brendan Keating; Diane Gilbert-Diamond
Journal:  Hum Genet       Date:  2016-11-15       Impact factor: 4.132

2.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

3.  PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).

Authors:  Shefali S Verma; Alex T Frase; Anurag Verma; Sarah A Pendergrass; Shaun Mahony; David W Haas; Marylyn D Ritchie
Journal:  Pac Symp Biocomput       Date:  2016

Review 4.  The genetics of alcohol dependence: advancing towards systems-based approaches.

Authors:  R H C Palmer; J E McGeary; S Francazio; B J Raphael; A D Lander; A C Heath; V S Knopik
Journal:  Drug Alcohol Depend       Date:  2012-07-31       Impact factor: 4.492

5.  Biology-Driven Gene-Gene Interaction Analysis of Age-Related Cataract in the eMERGE Network.

Authors:  Molly A Hall; Shefali S Verma; John Wallace; Anastasia Lucas; Richard L Berg; John Connolly; Dana C Crawford; David R Crosslin; Mariza de Andrade; Kimberly F Doheny; Jonathan L Haines; John B Harley; Gail P Jarvik; Terrie Kitchner; Helena Kuivaniemi; Eric B Larson; David S Carrell; Gerard Tromp; Tamara R Vrabec; Sarah A Pendergrass; Catherine A McCarty; Marylyn D Ritchie
Journal:  Genet Epidemiol       Date:  2015-05-17       Impact factor: 2.135

6.  Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.

Authors:  Päivi Hirvensalo; Aleksi Tornio; Mikko Neuvonen; Tuija Tapaninen; Maria Paile-Hyvärinen; Vesa Kärjä; Ville T Männistö; Jussi Pihlajamäki; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

Review 7.  Chapter 11: Genome-wide association studies.

Authors:  William S Bush; Jason H Moore
Journal:  PLoS Comput Biol       Date:  2012-12-27       Impact factor: 4.475

Review 8.  A survey about methods dedicated to epistasis detection.

Authors:  Clément Niel; Christine Sinoquet; Christian Dina; Ghislain Rocheleau
Journal:  Front Genet       Date:  2015-09-10       Impact factor: 4.599

9.  Genomic analyses with biofilter 2.0: knowledge driven filtering, annotation, and model development.

Authors:  Sarah A Pendergrass; Alex Frase; John Wallace; Daniel Wolfe; Neerja Katiyar; Carrie Moore; Marylyn D Ritchie
Journal:  BioData Min       Date:  2013-12-30       Impact factor: 2.522

Review 10.  Analysis pipeline for the epistasis search - statistical versus biological filtering.

Authors:  Xiangqing Sun; Qing Lu; Shubhabrata Mukherjee; Shubhabrata Mukheerjee; Paul K Crane; Robert Elston; Marylyn D Ritchie
Journal:  Front Genet       Date:  2014-04-30       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.